Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50

PHASE3TerminatedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

July 21, 2021

Study Completion Date

July 21, 2021

Conditions
COVID-19SARS-CoV-2
Interventions
DRUG

Ivermectin

Round and white tablets

DRUG

Placebo

Round and white tablets

Trial Locations (20)

15006

Complejo Hospitalario Universitario A Coruña-CHUAC, A Coruña

26006

Hospital San Pedro, Logroño

28006

Hospital Universitario de la Princesa, Madrid

28027

Clínica Universidad de Navarra - Madrid, Madrid

28040

Hospital Clínico San Carlos, Madrid

28050

HM Sanchinarro, Madrid

28250

HM Torrelodones, Torrelodones

28660

HM Montepríncipe, Boadilla del Monte

28938

HM Puerta del Sur, Móstoles

31008

Clínica Universidad de Navarra, Pamplona

Complejo Hospitalario de Navarra, Pamplona

37007

Complejo Asistencial Universitario de Salamanca, Salamanca

41009

Hospital Universitario Virgen de la Macarena, Seville

43005

Hospital Universitari de Tarragona Joan XXIII, Tarragona

04700

Hospital de Poniente, El Ejido

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08402

Hospital General de Granollers, Granollers

08028

Centro de Atención Primaria Les Corts, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Insud Pharma

INDUSTRY

NCT05993143 - Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 | Biotech Hunter | Biotech Hunter